Determination of busulfan in human plasma using an ELISA format

Therapeutic Drug Monitoring

Volumn 31, Issue 4, 2009, Pages 489-494

  Courtney, Jodi B ^a   Harney, Rebecca ^a   Li, Yunying ^a   Lundell, Gregory ^a   McMillin, Gwendolyn A ^b   Agarwal, Geeta ^b   Juenke, Joetta M ^b   Mathew, Anu ^c   Gonzalez Espinoza, Rita ^c   Fleisher, Martin ^c   Salamone, Salvatore J ^a  

^a SALADAX BIOMEDICAL INC   (United States)

^b ARUP LABORATORIES   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Busulfan; ELISA; Immunoassay

Indexed keywords

BUSULFAN; DRUG METABOLITE; MONOCLONAL ANTIBODY; TETRAHYDROTHIOPHENE; TETRAHYDROTHIOPHENE 3 OL 1,1 DIOXIDE; TETRAMETHYL SULFONE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CLINICAL PRACTICE; CONTROLLED STUDY; CROSS REACTION; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL;

ALKYLATING AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; REFERENCE STANDARDS;

EID: 68449092610     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181a8c99c     Document Type: Article

References (24)

1. Goldman JM, Horowitz MM. International Bone Marrow Transplant Registry. Int J Hematol Suppl. 2002;76:393-397.
2. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61.
3. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20:18-25.
4. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230.
5. Hassan M. The role of busulfan in bone marrow transplantation. Med Oncol. 1999;16:166-176.
6. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan concentrations on the outcome of transplantation. Blood. 1997;89:3055-3060.
7. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31-42.
8. McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30:167-173.
9. Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). Anticancer Res. 1994;14:2363-2370.
10. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002;8:477-485.
11. Ljungman P, Hassan M, Békássy AN, et al. Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone Marrow Transplant. 1995;15:869-871.
12. Copelan EA, Bechtel TP, Avalos BR, et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant. 2001;27:1121-1124.
13. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28:743-751.
14. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet. 2000;39:155-165.
15. Hoffer E, Akria L, Tabak A, et al. A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation. Ther Drug Monit. 2004;26:331-335.
16. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8:468-476.
17. Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007;13:56-64.
18. Petros WF, Evans WE. Anticancer Agents. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring. 4th ed. Baltimore, MD: Lippincott, Williams and Wilkins; 2006:617-636.
19. Lai WK, Pang CP, Law LK, et al. Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem. 1998;44:2506-2510.
20. Mürdter TE, Coller J, Claviez A, et al. Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electospray mass spectrometry. Clin Chem. 2001;47:1437-1442.
21. Quernin MH, Poonkuzhali B, Médard Y, et al. High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol. J Chromatogr B Biomed Sci Appl. 1999;721:147-152.
22. Peris JE, Latorre JA, Castel V, et al. Determination of busulfan in human plasma using high-performance liquid chromatography with pre-column derivatization and fluorescence detection. J Chromatogr B Biomed Sci Appl. 1999;730:33-40.
23. Kellogg MD, Law T, Sakamoto M, et al. Tandem mass spectrometry method for the quantification of serum busulfan. Ther Drug Monit. 2005;27:625-629.
24. Salamone S, Courtney JB, He S, Saladax Biomedical Inc. Busulfan Immunoassay, US Patent # 7,148,024, December 12, 2006.